UM-171

Research use only, not for human use.

UM-171 is a potent agonist of human hematopoietic stem cell self-renewal.

UM-171 is a potent agonist of human hematopoietic stem cell self-renewal, shows 10 to 20 times more potent than UM729 with effective concentrations of 17 to 19 nM; enables a robust ex vivo expansion of human CB cells with functionally validated long-term in vivo repopulating capability.Blood Cancer Phase 2 Clinical.

UM171 (50-100 nM) significantly increases CD34+ CD43+ and CD34+ CD45+ hematopoietic progenitors. UM171 enhances the derivation of hematopoietic cells at multiple developmental steps. UM171 enhances de novo generation of hematopoietic progenitor cells from hPSCs at multiple phases during hematopoietic differentiation in vitro. UM171 shows no effect on erythroid development, but inhibits erythroid maturation. UM171 treatment enhances the engraftment potential of CD34+ macaque cells by threefold. UM171 attenuates cell differentiation and promotes ex vivo expansion of primitive human hematopoietic cells, and promotes expansion of LT-HSCs. UM171 treatment results in down-regulation of AhR target genes such as CYP1B1, CYP1A1, and AhRR.

——

UM171

Others

Other Targets

Other Targets

Cancer

Blood cancer

1448724-09-1

487.94

C25H27N9

>98% (HPLC)

In Vitro:?DMSO : ≥ 75 mg/mL (165.37 mM)

N[C@H]1CC[C@H](NC2=C3C(NC4=C3C=CC(C5=NN(C)N=N5)=C4)=NC(CC6=CC=CC=C6)=N2)CC1

(1r,4r)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine

(-20℃)

With Ice Pack

≥ 2 years